uniQure NV Company Profile (NASDAQ:QURE)

About uniQure NV

uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease. Its product candidates include AMT-060 for Hemophilia B, AMT-110 for Sanfilippo B Syndrome, AAV2/GDNF for Parkinson's Disease, S100A1 for Congestive heart failure and Glybera for lipoprotein lipase deficiency (LPLD). For the AMT-060, the Company is conducting a Phase I/II clinical trial. The AMT-110 is based on glial cell line-derived neurotrophic factor, which is being studied in an investigator-sponsored Phase I clinical study. The AMT-130 is used for the treatment of Huntington's disease, in which the Company has demonstrated preclinical proof of concept.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: QURE
CUSIP:

Key Metrics:

Previous Close: $8.19
50 Day Moving Average: $8.19
200 Day Moving Average: $10.18
52-Week Range: $6.68 - $22.93
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -2.70
P/E Growth: 0.00
Market Cap: $205.30M
Outstanding Shares: 25,129,000
Beta: 0.17

Profitability:

Net Margins: -537.62%
Return on Equity: -61.96%
Return on Assets: -29.15%

Debt:

Debt-to-Equity Ratio: 0.22%
Current Ratio: 7.92%
Quick Ratio: 7.90%

Additional Links:

Companies Related to uniQure NV:

Consensus Ratings for uniQure NV (NASDAQ:QURE) (?)

Ratings Breakdown:	10 Buy Ratings
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$29.11 (255.45% upside)

Analysts' Ratings History for uniQure NV (NASDAQ:QURE)

Show:

Date	Firm	Action	Rating	Price Target
8/29/2016	Leerink Swann	Reiterated Rating	Outperform	$27.00
8/19/2016	Piper Jaffray Cos.	Set Price Target	Buy	$26.00 -> $16.00
8/4/2016	HC Wainwright	Initiated Coverage	Buy	$21.00
7/28/2016	Jefferies Group	Set Price Target	Buy	$28.00
7/28/2016	Chardan Capital	Set Price Target	Buy	$35.00
7/28/2016	Cowen and Company	Reiterated Rating	Buy
6/15/2016	Oppenheimer Holdings Inc.	Reiterated Rating	Outperform	$23.00
6/15/2016	WallachBeth Capital	Lower Price Target	Buy	$60.00 -> $35.00
1/8/2016	Janney Montgomery Scott	Reiterated Rating	Buy
1/8/2016	Roth Capital	Reiterated Rating	Buy	$37.00
5/9/2015	BMO Capital Markets	Reiterated Rating	Outperform -> Positive

(Data available from 9/28/2014 forward)

Earnings History for uniQure NV (NASDAQ:QURE)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/28/2016
8/25/2016	Q2	($0.89)	($0.87)			View	N/A
5/31/2016	Q1	($0.82)	($0.93)			View	N/A
4/4/2016	Q415	($0.60)	($0.58)			View	N/A
11/30/2015	Q315	($0.64)	($1.14)			View	Listen
8/27/2015	Q215	($0.56)	($0.98)			View	N/A
6/11/2015	Q1	($0.82)	($0.69)	$9.50 million	$1.17 million	View	N/A
4/6/2015		($0.62)	($0.77)			View	N/A
12/1/2014		($0.53)	($0.61)	$2.00 million	$1.30 million	View	N/A
9/2/2014	Q214	($0.55)	($1.35)			View	N/A
6/6/2014		($0.45)	($0.52)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for uniQure NV (NASDAQ:QURE)

Current Year EPS Consensus Estimate: $-3.62 EPS
Next Year EPS Consensus Estimate: $-3.03 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	3	($0.94)	($0.63)	($0.75)
Q2 2016	3	($0.98)	($0.74)	($0.85)
Q3 2016	3	($1.00)	($0.77)	($0.87)
Q4 2016	3	($1.03)	($0.80)	($0.90)

(Data provided by Zacks Investment Research)

Dividend History for uniQure NV (NASDAQ:QURE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for uniQure NV (NASDAQ:QURE)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for uniQure NV (NASDAQ:QURE)

Date	Headline
	uniQure to Present at the Jefferies Gene Editing and Gene Therapy Summit in New York City - GlobeNewswire (press release) (NASDAQ:QURE) globenewswire.com - September 28 at 12:09 PM
	uniQure to Present at the Jefferies Gene Editing and Gene Therapy Summit in New York City (NASDAQ:QURE) finance.yahoo.com - September 26 at 11:47 AM
	uniQure : Announces Management and Board Changes (NASDAQ:QURE) www.4-traders.com - September 22 at 6:41 PM
	BRIEF-Uniqure NV says Matthew Kapusta Appointed Interim CEO (NASDAQ:QURE) www.reuters.com - September 22 at 6:41 PM
	uniQure Announces Management and Board Changes (NASDAQ:QURE) finance.yahoo.com - September 22 at 6:41 PM
	Stock Perspective: uniQure N.V. (NASDAQ:QURE) Company Earnings Watch - Frisco Fastball (NASDAQ:QURE) friscofastball.com - September 17 at 6:27 PM
	What are Research Firms Saying About uniQure N.V. (NASDAQ:QURE)? - Frisco Fastball (NASDAQ:QURE) friscofastball.com - September 17 at 11:24 AM
	uniQure : Receives NASDAQ Deficiency Letter Related to Board Composition (NASDAQ:QURE) www.4-traders.com - September 16 at 6:44 PM
	Sell-side Consensus Sees uniQure N.V. (NASDAQ:QURE) Going Where Near-Term? - Frisco Fastball (NASDAQ:QURE) friscofastball.com - September 16 at 10:31 AM
	Analysts Take: uniQure N.V. (NASDAQ:QURE) Projected Earnings & Price Targets - Frisco Fastball (NASDAQ:QURE) friscofastball.com - September 16 at 10:31 AM
	uniQure Receives NASDAQ Deficiency Letter Related to Board Composition - GlobeNewswire (press release) (NASDAQ:QURE) globenewswire.com - September 16 at 10:31 AM
	uniQure Receives NASDAQ Deficiency Letter Related to Board Composition (NASDAQ:QURE) finance.yahoo.com - September 16 at 10:31 AM
	7:16 am uniQure receives Nasdaq deficiency letter stating the co is not in compliance with the requirement that the majority of Board members be independent Directors (NASDAQ:QURE) finance.yahoo.com - September 16 at 10:31 AM
	BRIEF-Uniqure Q2 loss per share eur 0.77 (NASDAQ:QURE) www.reuters.com - August 25 at 7:11 PM
	UniQure reports 2Q loss (NASDAQ:QURE) finance.yahoo.com - August 25 at 7:11 PM
	uniQure Announces Financial Results For Second Quarter 2016 and Update on Company Progress (NASDAQ:QURE) finance.yahoo.com - August 25 at 7:11 PM
	Is uniQure N.V. (NASDAQ:QURE) a Buy According to the Crowd? - Post News (NASDAQ:QURE) www.kentuckypostnews.com - August 23 at 7:10 PM
	Stock Moving Up in Session: uniQure N.V. (NASDAQ:QURE) - Post News (NASDAQ:QURE) www.kentuckypostnews.com - August 22 at 6:56 PM
	uniQure to Present at Upcoming Investor Conferences in September - GlobeNewswire (press release) (NASDAQ:QURE) globenewswire.com - August 17 at 7:23 PM
	uniQure to Present at Upcoming Investor Conferences in September (NASDAQ:QURE) finance.yahoo.com - August 17 at 10:03 AM
	One of the Best Biotech Stocks to Buy Could Return 52% in One Year (NASDAQ:QURE) moneymorning.com - August 3 at 7:24 PM
	Pfizer Inc. (PFE) to Explore Gene Therapy Portfolio (NASDAQ:QURE) www.thecountrycaller.com - August 2 at 12:00 PM
	Pfizer To Acquire Gene-Tech Company -- WSJ (NASDAQ:QURE) www.nasdaq.com - August 2 at 12:00 PM
	Pfizer acquires Bamboo Therapeutics (NASDAQ:QURE) www.tradearabia.com - August 2 at 12:00 PM
	Pfizer acquires Bamboo Therapeutics in $645 million deal (NASDAQ:QURE) www.poandpo.com - August 1 at 6:49 PM
	Pfizer Just Spent about $645 Million to Buy This Gene Therapy Company (NASDAQ:QURE) fortune.com - August 1 at 6:49 PM
	Pfizer to Buy Gene Therapy Company Bamboo Therapeutics (NASDAQ:QURE) www.nasdaq.com - August 1 at 6:49 PM
	Pfizer to buy gene therapy company Bamboo (NASDAQ:QURE) www.marketwatch.com - August 1 at 11:43 AM
	Pfizer acquires Bamboo Therapeutics to beef up gene therapy arsenal (NASDAQ:QURE) www.channelnewsasia.com - August 1 at 11:43 AM
	uniQure (QURE) Announces Updated Data from Ongoing Phase I/II trial of AMT-060 - StreetInsider.com (NASDAQ:QURE) www.streetinsider.com - July 28 at 10:19 AM
	BRIEF-Uniqure presents updated clinical data in patients with severe Hemophilia B - Reuters (NASDAQ:QURE) www.reuters.com - July 28 at 10:19 AM
	uniQure Presents Updated Clinical Data in Patients with Severe Hemophilia B Demonstrating up to 9 Months of Sustained Levels of Factor IX Activity and Therapeutic Effect (NASDAQ:QURE) www.publicnow.com - July 27 at 2:28 PM
	New Broker Ratings For Uniqure BV (NASDAQ:QURE) - FTSE News (NASDAQ:QURE) www.ftsenews.co.uk - July 25 at 7:11 PM
	uniQure N.V. (NASDAQ:QURE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:QURE) www.engelwooddaily.com - July 21 at 7:23 PM
	EPS Roundup: BJ's Restaurants, Inc. (NASDAQ:BJRI), uniQure N.V. (NASDAQ:QURE), Six Flags Entertainment ... - Engelwood Daily (NASDAQ:QURE) www.engelwooddaily.com - July 20 at 7:54 PM
	Equity Roundup: Stock Performance Focus on uniQure N.V. (NASDAQ:QURE) - Press Telegraph (NASDAQ:QURE) presstelegraph.com - July 20 at 9:52 AM
	As Gene Therapies Disrupt Big Pharma, Here's How to Get Your Piece of the Action (NASDAQ:QURE) moneymorning.com - July 19 at 7:10 PM
	How Many Uniqure NV (NASDAQ:QURE)'s Analysts Are Bearish? - Consumer Eagle (NASDAQ:QURE) www.consumereagle.com - July 19 at 8:00 AM
	Earnings Focus and Crowd Sourced Sentiment Review for uniQure N.V. (NASDAQ:QURE) - TGP (NASDAQ:QURE) telanaganapress.com - July 19 at 8:00 AM
	Uniqure BV (NASDAQ:QURE) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:QURE) www.fiscalstandard.com - July 17 at 6:27 PM
	Uniqure NV Ord (NASDAQ:QURE) Shorted Shares Increased 4.23% After Market Selling - Consumer Eagle (NASDAQ:QURE) www.consumereagle.com - July 17 at 6:27 PM
	Uniqure NV Just Recorded A Sigfniciant Decline - Consumer Eagle (NASDAQ:QURE) www.consumereagle.com - July 16 at 6:31 PM
	Will uniQure N.V. (NASDAQ:QURE) Surprise Analysts? - Investor Newswire (NASDAQ:QURE) www.investornewswire.com - July 14 at 10:40 AM
	Analyst Target and Average Rating Watch: uniQure N.V. (NASDAQ:QURE) - Press Telegraph (NASDAQ:QURE) presstelegraph.com - July 14 at 10:40 AM
	uniQure Announces Oral Presentation of Updated Results for AMT-060 at the World Federation of Hemophilia (WFH) 2016 World Congress (NASDAQ:QURE) finance.yahoo.com - July 11 at 1:54 PM
	BRIEF-UniQure appoints Jonathan Garen as chief business officer - Reuters (NASDAQ:QURE) www.reuters.com - July 9 at 6:25 PM
	Uniqure NV Ord (NASDAQ:QURE) Sellers Increased By 4.23% Their Shorts - Press Telegraph (NASDAQ:QURE) presstelegraph.com - July 8 at 9:56 AM
	uniQure NV Stock Momentum at Critical Inflection Point - CML News (NASDAQ:QURE) news.cmlviz.com - July 8 at 9:56 AM
	Company Stock Focus for uniQure N.V. (NASDAQ:QURE): Which Way Will Shares Head? - Press Telegraph (NASDAQ:QURE) presstelegraph.com - July 7 at 9:51 AM
	Company Update (NASDAQ:QURE): Uniqure NV Appoints Jonathan Garen as Chief Business Officer - Smarter Analyst (NASDAQ:QURE) www.smarteranalyst.com - July 7 at 9:51 AM